Markets:

Overview

News

Currencies

International

Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.580 -0.130 (-4.80%)

Streaming Delayed Price Updated: 1:10 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

March 28, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

5 Value Stocks In The Healthcare Sector ↗

March 27, 2023

Via Benzinga

Earnings Scheduled For March 27, 2023 ↗

March 27, 2023

Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its...

Via Benzinga

Earnings Preview For Acumen Pharmaceuticals ↗

March 24, 2023

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

March 24, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 26, 2022

Via Benzinga

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

March 27, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

March 22, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

March 20, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

March 08, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

February 13, 2023

Topline results including safety and proof-of-mechanism data expected in third quarter of 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

January 04, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

November 14, 2022

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 14, 2022

Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3...

Via Benzinga

Earnings Preview: Acumen Pharmaceuticals ↗

November 11, 2022

Acumen Pharmaceuticals (NASDAQ:ABOS) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that Acumen...

Via Benzinga

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

November 09, 2022

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

November 07, 2022

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

November 01, 2022

Clinical development plan published in Journal of Prevention of Alzheimer’s Disease

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 24, 2022

Gainers Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million.

Via Benzinga

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

October 24, 2022

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 12, 2022

Gainers

Via Benzinga

How Is The Market Feeling About Acumen Pharmaceuticals? ↗

October 12, 2022

Acumen Pharmaceuticals's (NASDAQ:ABOS) short percent of float has risen 237.39% since its last report. The company recently reported that it has 2.36 million shares sold short, which is 7.76% of all...

Via Benzinga

RPM International, Lamb Weston And Some Other Big Stocks Moving Higher On Wednesday ↗

October 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Bank of America To $36? Plus This Analyst Slashes PT On Citigroup ↗

October 05, 2022

Morgan Stanley cut Bank of America Corporation (NYSE: BAC) price target from $40 to $36. Bank of America shares fell 2.4% to $31.62 on Wednesday.

Via Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday ↗

September 29, 2022

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

Nasdaq Surges Over 150 Points; Gold Rises 2% ↗

September 28, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 28, 2022

Gainers

Via Benzinga

Why Is Prothena (PRTA) Stock Up 75% Today? ↗

September 28, 2022

Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.